Mode
Text Size
Log in / Sign up
N/A N=431 Diagnostic

A Multi-Center Study of Near-Infrared Spectroscopy (NIRS) for Hematoma Detection

TBI (Traumatic Brain Injury)

Enrolled (actual)
431
Serious AEs
0.0%
Results posted
Dec 2013
Primary outcome: Primary: 1) Sensitivity of the Near-Infrared Spectroscopy (NIRS) Measurements for Identifying Intracranial Hematomas Due to Trauma. 2) Specificity of the Near-Infrared Spectroscopy (NIRS) Measurements for Identifying Intracranial Hematomas Due to Trauma. — 44; 25; 244; 6 Number of participants

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Infrascanner (Device)
Age
Pediatric, Adult, Older Adult
Sex
All
Sponsor
InfraScan, Inc.
Primary completion
Jan 2011

Outcome Measures

OutcomeResultp-value
PRIMARY
1) Sensitivity of the Near-Infrared Spectroscopy (NIRS) Measurements for Identifying Intracranial Hematomas Due to Trauma. 2) Specificity of the Near-Infrared Spectroscopy (NIRS) Measurements for Identifying Intracranial Hematomas Due to Trauma.
44; 25; 244; 6

Summary

The purposes of this study are: 1. To determine the sensitivity and specificity of the Near-Infrared Spectroscopy (NIRS) measurements for identifying intracranial hematomas due to trauma. 2. To determine the reproducibility of the Near-Infrared Spectroscopy (NIRS) measurements with different operators and at different centers

Eligibility Criteria

Inclusion Criteria

  • Undergoing a CT scan within 12 hours of their head injury. The criteria for obtaining a CT scan will be based on the standard of care, but generally all patients with a moderate or severe head injury will receive a CT scan on admission to the hospital, and only patients who undergo a CT will be enrolled into the study. The non-contrast CT will be performed according to standard methods.

Exclusion Criteria

  • 12 hours or more since injury.
  • Massive scalp lacerations, avulsions, and hematomas The limitation to injury within 12 hours is necessary because as hematoma blood is metabolized, the absorbance characteristics change.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00576147). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search